The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Open accessAbstract
Agonists of the nuclear receptor PPARγ are therapeutically used to combat hyperglycaemia associated with the metabolic syndrome and type 2 diabetes. In spite of being effective in normalization of blood glucose levels, the currently used PPARγ agonists from the thiazolidinedione type have serious side effects, making the discovery of novel ligands highly relevant. Natural products have proven historically to be a promising pool of structures for drug discovery, and a significant research effort has recently been undertaken to explore the PPARγ-activating potential of a wide range of natural products originating from traditionally used medicinal plants or dietary sources. The majority of identified compounds are selective PPARγ modulators (SPPARMs), transactivating the expression of PPARγ-dependent reporter genes as partial agonists. Those natural PPARγ ligands have different binding modes to the receptor in comparison to the full thiazolidinedione agonists, and on some occasions activate in addition PPARα (e.g. genistein, biochanin A, sargaquinoic acid, sargahydroquinoic acid, resveratrol, amorphastilbol) or the PPARγ-dimer partner retinoid X receptor (RXR; e.g. the neolignans magnolol and honokiol). A number of in vivo studies suggest that some of the natural product activators of PPARγ (e.g. honokiol, amorfrutin 1, amorfrutin B, amorphastilbol) improve metabolic parameters in diabetic animal models, partly with reduced side effects in comparison to full thiazolidinedione agonists. The bioactivity pattern as well as the dietary use of several of the identified active compounds and plant extracts warrants future research regarding their therapeutic potential and the possibility to modulate PPARγ activation by dietary interventions or food supplements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Indian Medicinal Plants: An Illustrated Dictionary
(2007) · Springer eBooks · doi:10.1007/978-0-387-70638-2 · Cited by 9,201
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“However, some meta-analyses indicated that among patients with impaired glucose tolerance or type 2 diabetes the use of rosiglitazone for at least 12 months was associated with a significantly increased risk of myocardial infarction and heart failure, as well as with an elevated risk of cardiovascular mortality [91–95…”
ResultAdipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Cited by
Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects
Zhang, H., & Tsao, R. (2016) · Current Opinion in Food Science · doi:10.1016/j.cofs.2016.02.002 · Cited by 1,519
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Natural Products for the Treatment of Type 2 Diabetes Mellitus
Ríos, J., Francini, F., & Schinella, G. (2015) · Planta Medica · doi:10.1055/s-0035-1546131 · Cited by 446
The Prevalence of Metabolic Syndrome in Children: A Systematic Review of the Literature
Friend, A., Craig, L., & Turner, S. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0122 · Cited by 354
Health benefits of dietary marine DHA/EPA-enriched glycerophospholipids
Zhang, T.-T., Xu, J., Wang, Y.-M., & Xue, C.-H. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.100997 · Cited by 339
Interplay between food and gut microbiota in health and disease
Danneskiold-Samsøe, N. B., Dias de Freitas Queiroz Barros, H., Santos, R., Bicas, J. L., Cazarin, C. B. B., Madsen, L., Kristiansen, K., Pastore, G. M., Brix, S., & Maróstica Júnior, M. R. (2019) · Food Research International · doi:10.1016/j.foodres.2018.07.043 · Cited by 268
Anti-obesogenic and antidiabetic effects of plants and mushrooms
Martel, J., Ojcius, D. M., Chang, C.-J., Lin, C.-S., Lu, C.-C., Ko, Y.-F., Tseng, S.-F., Lai, H.-C., & Young, J. D. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.142 · Cited by 266
Markers and Biomarkers of Endothelium: When Something Is Rotten in the State
Goncharov, N. V., Nadeev, A. D., Jenkins, R. O., & Avdonin, P. V. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9759735 · Cited by 190
“For example, many natural products are agonists of PPARγ and/or PGC-1α, and the bioactivity pattern of the active compounds and plant extracts warrants future research regarding their therapeutic potential and the possibility to modulate PPARγ/PGC-1α activation by dietary interventions or food supplements [258].”
Chen, Y., Yang, B., Ross, R. P., Jin, Y., Stanton, C., Zhao, J., Zhang, H., & Chen, W. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05744 · Cited by 185
Ali, S. H., Madhana, R. M., K.V., A., Kasala, E. R., Bodduluru, L. N., Pitta, S., Mahareddy, J. R., & Lahkar, M. (2015) · Steroids · doi:10.1016/j.steroids.2015.05.010 · Cited by 145
“Pharmacological studies have demonstrated antioxidant [22], anti-inflammatory [23], anti-diabetic [24], cancer chemopreventive [25], cardio-protective [21] and neuroprotective [26] properties as well as the capacity to inhibit the development of osteoporosis [27] and menopausal symptoms [28].”
In-depth analysis of lupeol: delving into the diverse pharmacological profile
Dalimunthe, A., Carensia Gunawan, M., Dhiya Utari, Z., Dinata, M. R., Halim, P., Estherina S. Pakpahan, N., Sitohang, A. I., Sukarno, M. A., Yuandani, Harahap, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461478 · Cited by 50
Neuron Membrane Trafficking and Protein Kinases Involved in Autism and ADHD
Kitagishi, Y., Minami, A., Nakanishi, A., Ogura, Y., & Matsuda, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023095 · Cited by 37
Metadata
- Authors
- Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster, D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M., & Atanasov, A. G.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 92
- Issue
- 1
- Pages
- 73-89
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2067942093
- Cited by
- 594
- References
- 236
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.